β-III-spectrin N-terminus is required for high-affinity actin binding and SCA5 neurotoxicity

por Denha, Sarah A., Atang, Alexandra E., Hays, Thomas S., Avery, Adam W.
Publicado 2022

Increased Actin Binding Is a Shared Molecular Consequence of Numerous SCA5 Mutations in β-III-Spectrin

por Atang, Alexandra E., Keller, Amanda R., Denha, Sarah A., Avery, Adam W.
Publicado 2023

Increased actin binding is a shared molecular consequence of numerous spinocerebellar ataxia mutations in β-III-spectrin

por Atang, Alexandra E., Keller, Amanda R., Denha, Sarah A., Avery, Adam W.
Publicado 2023

Novel drug discovery platform for spinocerebellar ataxia, using fluorescence technology targeting β-III-spectrin

por Rebbeck, Robyn T., Andrick, Anna K., Denha, Sarah A., Svensson, Bengt, Guhathakurta, Piyali, Thomas, David D., Hays, Thomas S., Avery, Adam W.
Publicado 2020

Early-phase drug discovery of β-III-spectrin actin-binding modulators for treatment of spinocerebellar ataxia type 5

por Guhathakurta, Piyali, Rebbeck, Robyn T., Denha, Sarah A., Keller, Amanda R., Carter, Anna L., Atang, Alexandra E., Svensson, Bengt, Thomas, David D., Hays, Thomas S., Avery, Adam W.
Publicado 2023